A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer

N. Dickler, Maura; S. Rugo, Hope; A. Eberle, Carey; Brogi, Edi; F. Caravelli, James; S. Panageas, Katherine; Boyd, Jeff; M. Yeh, Benjamin; Lake, Diana; T. Dang, Chau; Gilewski, Teresa; Bromberg, Jacqueline; D. Seidman, Andrew; D’Andrea, Gabriella; M. Moasser, Mark; Melisko, M.E.; W. Park, John; Dancey, Janet; Norton, Larry; A. Hudis, Clifford

doi:10.1158/1078-0432.ccr-08-0141

Public

A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer

Published in Clinical Cancer Research • Dec 1, 2008

Authors:

Maura N. Dickler

Hope S. Rugo

Carey A. Eberle

Abstract

PURPOSE: To evaluate the efficacy and toxicity of erlotinib plus bevacizumab in patients with metastatic breast cancer (MBC), targeting the epidermal growth factor receptor (EGFR/HER1) and the vascular endothelial growth factor (VEGF) pathway. EXPERIMENTAL DESIGN: Thirty-eight patients with MBC were...

Subject

Erlotinib

Bevacizumab

Metastatic breast cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!